According to an amended 13D filing with the Securities and Exchange Commission, Nelson Obus and Joshua Landes‘ Wynnefield Capital decreased its stake in Omega Protein Corp (NYSE:OME) to 1.37 million shares, which represent 6.2% of the company’s outstanding shares. According to its 13F filing for the end of June, the stake previously consisted of 1.77 million common shares.
Omega Protein is a food business company that produces nutritious products and operates in two sectors: animal nutrition and human nutrition. Over the past 12 months, the company’s shares have gained 39.77%. For the second quarter of 2016, Omega Protein reported earnings per share of $0.62 and revenue of $112.7 million, compared to EPS of $0.43, and revenue of $93.2 million for the same period a year earlier. Earlier this month, DA Davidson boosted its price target on Omega Protein’s stock to $26 from $20, maintaining a ‘Neutral’ rating on it, while Wunderlich downgraded the stock to ‘Hold’ from ‘Buy’ but raised its price target on it to $26 from $22, and Pivotal Research boosted its price target to $30 from $25, and has a ‘Buy’ rating on the stock.
Investors in our database long Omega Protein Corp (NYSE:OME) at the end of June, aside from Wynnefield Capital, included Peter Algert and Kevin Coldiron’s Algert Coldiron Investors, with a position worth $874,000, Louis Navellier’s Navellier & Associates, which held a position valued at $284,000, and Gavin Saitowitz and Cisco J. Del Valle’s Springbok Capital. Some of the new investors in Omega Protein Corp (NYSE:OME) during the second quarter were Ken Griffin’s Citadel Investment Group, which had a $524,000 position in the company at the end of the period, and Robert B. Gillam’s McKinley Capital Management, which initiated a position worth $5,000 at the end of June.
You can access the original SEC filing by clicking here.
Ownership Summary Table
|Name||Sole Voting Power||Shared Voting Power||Sole Dispositive Power||Shared Dispositive Power||Aggregate Amount Owned Power||Percent of Class|
|Wynnefield Partners Small Cap Value||442,982||0||442,982||0||442,982||2.0%|
|Wynnefield Partners Small Cap Value||730,327||0||730,327||0||730,327||3.3%|
|Wynnefield Small Cap Value Offshore Fund, Ltd. (No||113,754||0||113,754||0||113,754||0.5%|
|Wynnefield Capital, Inc. Profit Sharing Money Purchase Plan||85,000||0||85,000||0||85,000||0.4%|
|Wynnefield Capital Management||1,173,309||0||1,173,309||0||1,173,309||5.3%|
|Wynnefield Capital, Inc. 13-3688495||113,754||0||113,754||0||113,754||0.5%|
Page 1 of 14 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Amendment No. 7)
Under the Securities Exchange Act of 1934
(Name of Issuer)
(Title of Class of Securities)
Wynnefield Partners Small Cap Value, L.P.
450 Seventh Avenue, Suite 509
New York, New York 10123
Attention: Mr. Nelson Obus
Jeffrey S. Tullman, Esq.
Kane Kessler, P.C.
1350 Avenue of the Americas, 26th Floor
New York, New York 10019
(Name, Address and Telephone
Number of Person Authorized to Receive Notices and Communications)
(Date of Event which requires Filing of
If the filing person has previously filed
a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because
of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨